Device innovations, demographics and hospital austerity are all factors helping to drive the global medical device market to more than $300 billion, according to healthcare market research publisher Kalorama Information. In its report, " The Global Market for Medical Devices," Kalorama Informations analysts predict a $312 billion medical device market in 2011.
"There are many drivers on the upside for medical devices," says Kalorama Informations publisher, Bruce Carlson. "Demand for healthcare services in emerging nations, the need for reducing hospital stays and the aging world population are the key ones."
The market for medical devices is vast and, in Kalorama Informations report, products as different as complex MRI machines, laparoscopic surgical equipment, wheelchairs and medical gloves are included in the category.
Kalorama sees roughly 4 percent to 6 percent growth for the next few years in the global device market, which was valued at $290 billion in 2009. Growth has been slow the past few years, according to the report, given the world recession. But as the economy recovers and new middle class customers in emerging markets demand better healthcare services, the report predicts the pace of revenue growth to increase. According to Carlson, the average growth rate belies that in some categories growth is much higher than the average discussed in the report.
"Some categories of medical devices are commoditized and competition will hold prices in check, while in other areas revenues will flourish," Carlson says. "Patient monitoring, oxygen systems, home dialysisanything that can reduce hospital stays and keep patients at home with their familyare seeing faster revenue growth."
There are hundreds of companies operating in the global medical device market, but according to the report, the majority of revenues will be earned by 30 of the top companies, among them: Johnson & Johnson, Siemens Healthcare, Medtronic, GE Healthcare and Baxter.
Kalorama Informations estimates are based on industry interviews, a review of the firms own previous research into specific device markets and annual reports of major companies.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.